

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application number	10/574,560
Filing date	1 February 2007
First Named Inventor	Serdar SEL et al
Art Unit	1635
Examiner name	Bowman, A
Attorney Docket Number	23593

U.S. PATENTS

Ex. Initials	Cite No.	Patent Number	Kind Code	Issue Date	Name of Patentee or Applicant	Pages, columns, lines where Relevant Passages or relevant Figs. appear
	1	7355035		8 April 2008	D.G. ATKINS	
	2					
	3					
	4					
	5					

U.S. PATENT APPLICATION PUBLICATIONS

Ex. Initials	Cite No.	Publication Number	Kind Code	Publication date	Name of Patentee or Applicant	Pages, columns, lines where Relevant Passages or relevant Figs. appear
	1					
	2					
	3					

FOREIGN PATENT DOCUMENTS

Ex. Initials	Cite No.	Foreign Document Number	Country Code	Kind Code	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where Relevant Passages or relevant Figs. appear	Tra ?
	1	WO 00/51621			8 Sept. 2000	Epigenesis Pharm		
	2	WO 01/11023			15 Feb. 2001	Johnson & Johnson		
	3							
	4							

NON-PATENT LITERATURE

Ex. Initials	Cite No.	AUTHOR NAME, Article Title, Book Title, Date, Page(s), Vol/Iss. No., Publisher, City/Country
	1	Santoro S W et al; A general purpose RNA-cleaving ...; Nat. Acad. Sci., Vol. 94, April 1997; pgs. 4262-4266
	2	Sun L Q et al; Catalytic nucleic acids ...; Pharma. Review; Williams & Wilkins Inc.; Sept. 2000; pgs. 325-347
	3	Imagawa S et al; Negative regulation of the erythropoietin ...; Blood, W.B. Saunders; Feb. 1997; pgs. 1430 - 1439

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

14 January 2011

KF Ross PC
Customer Number 535
5683 Riverdale Ave. Box 900
Bronx (Riverdale), NY 10471
23593PTOSB81.WPD